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Abstract 
Escalating drug prices have catalysed the generation of numerous “value frameworks” 
with the aim of informing payers, clinicians and patients on the assessment process of 
new medicines for the purpose of coverage and treatment selection decisions.  
Although this is an important step towards a more inclusive Value Based Assessment 
(VBA) approach, aspects of these frameworks are based on weak methodologies and 
could potentially result in misleading recommendations or decisions.  
A Multiple Criteria Decision Analysis (MCDA) methodological process based 
on Multi Attribute Value Theory (MAVT) is adopted for building a multi-criteria 
evaluation model. A five-stage model-building process is followed, using a top-down 
“value-focused thinking” approach, involving literature reviews and expert 
consultations. A generic value tree is structured capturing decision-makers’ concerns 
for assessing the value of new medicines in the context of Health Technology 
Assessment (HTA) and in alignment with decision theory.  
The resulting value tree (Advance Value Tree) spans three levels of criteria 
(top level criteria clusters, mid-level criteria, bottom level sub-criteria or attributes) 
relating to five key domains that can be explicitly measured and assessed: (a) burden 
of disease, (b) therapeutic impact, (c) safety profile (d) innovation level, and (e) 
socioeconomic impact. A number of MAVT modelling techniques are introduced for 
operationalising (i.e. estimating) the model, for scoring the alternative options, 
assigning relative weights of importance to the criteria, and combining scores and 
weights.   
Overall, the combination of these MCDA modelling techniques for the 
elicitation and construction of value preferences across the generic value tree provides 
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a new value framework (Advance Value Framework) enabling the comprehensive 
measurement of value in a transparent and structured way. Given the flexibility to 
meet diverse requirements and become readily adaptable across different settings, it 
could be tested as a decision-support tool for decision-makers to aid coverage and 
reimbursement of new medicines.  
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1. Background  
Scarce resources, rising demand for health services, ageing populations and 
technological advances threaten the financial sustainability of many health care 
systems and render efficient and fair resource allocation a cumbersome task 
(Beauchamp, 2003; Eddy, 1991; Emanuel, 2000; Fleck, 2001; Rawls, 1999). 
Decision-making in health care is inherently complex as numerous objectives need to 
be balanced, usually through the involvement of many stakeholders. One set of tools 
used widely to improve efficiency in resource allocation is Health Technology 
Assessment (HTA). The use of HTA has expanded significantly over the past 20 years 
and it is now used to assess and appraise the value of new medical technologies as 
well as inform coverage decisions.  
Evidence-based medicine (G. Guyatt, 1992; Sackett et al., 1996), economic 
evaluations (Drummond & McGuire, 2001; Drummond et al., 2015), burden of 
disease estimates (Murray & Lopez, 1996), and budget impact analysis (Mauskopf et 
al., 2007) can be used to inform decisions on resource allocation. Nevertheless, they 
offer limited guidance to decision makers, as their results cannot be integrated and 
judged simultaneously and neither can the associated value trade-offs (Baltussen & 
Niessen, 2006). The use of economic evaluation techniques such as cost effectiveness 
analysis (CEA) has become the preferred analytical method adopted by many HTA 
agencies. However, all value-related concerns of decision-makers are not adequately 
reflected in a cost effectiveness model (Angelis et al., 2017). For example, the use of 
cost utility analysis (CUA) and the cost per unit of quality adjusted life year (QALY) 
has become the metric of choice for many HTA agencies when assessing and 
appraising value, although by definition the latter  only considers length of life in 
tandem with health related quality of life, and does not adequately capture social 
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value such as the wider innovation and socioeconomic impact (Brouwer et al., 2008; 
Wouters et al., 2015).  
Due to the complexity of these multiple criteria problems, decision-makers 
tend to adopt intuitive or heuristic approaches for simplification purposes, but as a 
consequence important information may be under-utilised or be altogether excluded 
leading to choices based on an ad-hoc priority setting process (Baltussen & Niessen, 
2006). Eventually the decision making process tends to be explicitly informed solely 
by evidence from economic evaluations, with social value concerns being considered 
on an implicit and ad-hoc basis. As a consequence, when faced with multiple trade-
offs across a range of societal values, decision makers seem to not be well equipped to 
make informed and rational decisions (Bazerman, 1998; McDaniels et al., 1999), 
therefore diminishing the reasonableness and credibility of the decision outcomes. It 
is probably the case that a more “rational” approach is needed that can simultaneously 
take into account the multiplicity of criteria, and that can aggregate the performance 
of alternative interventions across the criteria of interest while accounting for 
differences between their relative importance, therefore enabling the overall 
construction and analysis of decision makers’ preferences in a simple and transparent 
way (Angelis et al., 2016; Baltussen & Niessen, 2006). The multiple value 
frameworks initiatives that have emerged over the past few years aiming to aid 
reimbursement agencies, health care professionals and patients understand the value 
of new therapies and make better choices about their use serve as a testament to this 
particular gap (Neumann & Cohen, 2015).  
Some of the most prominent and well known value frameworks that have 
attracted high levels of attention include those proposed by the American College of 
Cardiology and the American Heart Association (ACC/AHA) (Anderson et al., 2014), 
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the American Society of Clinical Oncology (ASCO) (Schnipper et al., 2015), the 
European Society of Medical Oncology (ESMO) (Cherny et al., 2015), the Institute 
for Clinical and Economic Review (ICER) (Pearson, 2015), the Memorial Sloan 
Kettering Cancer Centre (MSKCC) (Bach, 2015), the National Comprehensive 
Cancer Network (NCCN) (NCCN, 2015), and the Working Group on Mechanisms of 
Coordinated Access to Orphan Medicinal Products (MoCA-OMP)  (Working Group 
on Mechanism of Coordinated Access to Orphan Medicinal Products, 2013) among 
others. These value frameworks adopt multiple criteria approaches in an attempt to 
decompose complex problems into slightly simpler ones and address these 
sequentially. As such, they are an important step towards a more inclusive Value 
Based Assessment (VBA) process despite being perceived as weak and atheoretical 
and potentially of little value for policy or clinical decision-making (Angelis & 
Kanavos, 2016a). Despite the proliferation of value frameworks, ‘value’ remains an 
elusive target and a wider consensus about what dimensions of value to include may 
still be some way off, with the potential exception of frameworks that are applied in 
clinical practice (as potential value dimensions are more restricted in nature).  
The use of multiple criteria decision analysis (MCDA) methods has been 
proposed as an alternative methodological approach for assessing the value of health 
care interventions in different contexts, ranging from licensing decisions at the 
marketing authorization stage (L. Phillips et al., 2011), to coverage decisions at the 
HTA stage (Thokala & Duenas, 2012), to treatment selection decisions at prescribing 
level (Tervonen et al., 2015). MCDA methods can be used for quantifying benefits, 
risks and uncertainties in order to aid the decision-making process, by considering an 
explicit set of criteria and their relative importance under a fully transparent process, 
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while incorporating a wide range of stakeholder views to express a more societal 
perspective.  
A methodological process towards the development of a robust MCDA 
framework observing key principles to ensure methodological robustness, consisting 
of different phases and stages for implementation in the context of HTA, has already 
been proposed (Angelis & Kanavos, 2016b). Possibly the most fundamental phase of 
the MCDA process with the highest impact on the overall outcomes relates to model 
building and the criteria selection phase, which influences the choice of the value 
concerns against which the alternative options will be assessed. 
In this paper we outline the development of a new value framework focusing on 
model building and criteria selection, describing the development of a generic value 
based model taking the form of a value tree for the purpose of assessing the value of 
new medicines in the context of HTA by capturing value for decision makers. 
Although in theory such a value tree can be generic for any type of health technology, 
including drugs, medical devices and other health interventions, for ease of 
illustration, we focus on new medicines. In Section 2 we discuss the theoretical 
foundations of MCDA, starting with the theoretical axioms of decision analysis that 
essentially address the question of “what is the basis of MCDA”. In section 3 we 
outline the methods for model building and the selection of different evaluation 
criteria. Section 4 presents the results involving the assembly of decision makers’ 
concerns into a comprehensive generic value tree, which provides insights into “what 
is value in the context of HTA”. Section 5 presents the discussion, introducing 
different MCDA methods, proposes ways to operationalise the value tree through a 
precise combination of MCDA techniques and addresses the question of “how to 
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apply MCDA in HTA” through the use of a new value framework.  Finally, section 6 
draws the main conclusions. 
 
2. Theoretical foundations  
Decision analysis was originally defined by Howard as “a logical procedure for the 
balancing of the factors that influence a decision” incorporating “uncertainties, values, 
and preferences in a basic structure that models the decision” (Howard, 1966). The 
logic behind decision analysis was described as divide and conquer whereby a 
complex problem is decomposed into simpler problems and each individual problem 
is analysed separately before all analyses are connected together, resulting in a 
program of action for the complex problem (Raiffa, 1968).  
The methodology of decision analysis is simplified to four main steps, notably 
(a) structure the decision problem; (b) assess possible impacts of each alternative; (c) 
determine preferences (values) of decision makers; and (d) evaluate and compare 
alternatives (R. L. Keeney, 1982; Raiffa, 1968). 
The main outcome of decision analysis theoretical axioms is that first, the 
utility of an alternative is the indication of its desirability, and second, that an 
alternative A with higher utility U(A) should be preferred to an alternative B with 
lower utility U(B), in other words expressing the rationality rule of utility 
maximisation, i.e. 
 
                                                                                                    (1) 
 
Decision analysis seems to be particularly useful for coping with the 
complexities arising from uncertainty and multiple conflicting objectives (Raiffa, 
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1968). Uncertainties can be traded-off against some value aspects of the outcomes, 
formally through the incorporation of probabilities. Similar trade-offs can be made 
among different objectives and their associated values. These trade-offs are 
judgements, depending on the decision maker’s assessment of the relative desirability 
of the available options across their dimensions in tandem with the relative 
importance of these dimensions. However, given that trade-offs are personal, there are 
no universal rules for making them, and they are therefore subjective in nature (von 
Winterfeldt & Edwards, 1986). By definition, decision-making is inherently 
subjective as it depends on individual utility and preferences. Therefore, the notion of 
rationality is used with the goal of making rational inferences and decisions. Possibly 
the most prominent of such criteria rules would be the maximisation of (expected) 
utility or value (Savage, 1954).  
In decision analysis there is a clear conceptual difference between value 
functions, which assess the marginal benefit of an option, and utility functions, which 
incorporate preferences, therefore assessing both marginal benefit and risk attitude. 
The former is employed for riskless choices and the latter for choices under 
uncertainty. Expectation mainly relates to the concept of probability theory, with 
expected utility or value being a weighted average of the pay-off for an outcome 
(utility or value) and its respective probability of actually occurring (von Winterfeldt 
& Edwards, 1986). Expected utility and expected value are, therefore, calculated in a 
similar way but the pay-offs in the former case correspond to subjective utilities rather 
than objective quantities, with their formal terminology being subjectively expected 
utilities (SEUs): both the utilities and the probabilities incorporated are numbers, but 
are subjective in nature giving rise to numerical subjectivity, the notion of subjective 
judgments expressed as numbers (von Winterfeldt & Fasolo, 2009).  In the context of 
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HTA, the evaluation of new medical technologies predominantly relates to the 
evidence-based assessment of their value by measuring their marginal benefits. 
Therefore we choose to use the value term rather than utility, which reduces the 
heterogeneity of the value judgements based on expected utility.  
 
The expected value (EV) of an event could then be written as  
          (2) 
 
Or alternatively as 
          (3) 
Where pi is the probability that event i will take place and vi is the value or pay-off 
associated with the event.  
Given that the evaluation of health care interventions as part of HTA predominantly 
relates to the assessment of their value using existing evidence and not expected 
evidence, for simplicity reasons we choose to detach expectation and the probability 
concept while assuming the existence of evidence for the measurement of marginal 
benefit. However, it could also be argued that in various cases absence of (satisfactory 
or adequate) evidence essentially introduces an expectation variable given the 
attached probabilities of the respective outcomes to take place (e.g. clinical outcome), 
especially as part of early-HTA settings, where a new medicine might still be under 
clinical development. 
The same axiomatic rule arising from (expected) value maximization could be 
adopted in the context of HTA: a medical technology A with higher (expected) value 
would be preferred over another medical technology B with lower (expected) value. 
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The term ‘preference’ would relate to coverage decisions (i.e. reimbursement) for the 
health care technology with the higher (expected) value, the aim being to maximise 
efficiency in resource allocation.  
The starting point for this discussion is that the value of new medical 
technologies is multidimensional and not limited to their clinical effect or benefit. 
Besides the traditional dual clinical consideration of health benefits and risks, taking 
the form of efficacy and safety considerations, or the emerging dual economic 
consideration of health benefits and costs, taking the form of health outcomes and 
costs per unit of outcome, other factors may also be important in determining the 
value of a new medicine. The severity and unmet need of the disease, the clinical 
novelty and convenience to patients, or the wider benefits to society have often been 
perceived as important considerations of value to decision makers and can contribute 
to the debate on efficient resource allocation (DH, 2010).    
Based on that, the value of new medical technologies can be illustrated as a 
function of different evaluation parameters, namely: 
   
         (4) 
 
where a, b, c, d,… n denote the different parameters of interest, i denotes the 
perception of a medical technology’s value in regards to a particular parameter based 
on the views of different stakeholders and j denotes the weight of the same parameter. 
Additionally, questions remain on how to incorporate the views of all relevant 
stakeholders and how to derive relative weights for the different parameters. 
Given that the value of new medical technologies is based on a multitude of 
value dimensions and the limitations of current approaches for their assessment in the 
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context of making resource allocation decisions, there is a need for an alternative 
methodological approach that encompasses multiple value domains explicitly, 
therefore a decision analysis method that addresses multiple attributes of benefit is 
required (Angelis et al., 2016). 
Among methodological tools for assessing value quantitatively as part of 
decision-making process, MCDA could be indicated as an ideal method, ordering a 
set of alternative options based on the degree to which a number of different 
objectives are achieved (Department for Communities and Local Government, 2009; 
R. L. Keeney & Raiffa, 1976). One of the main aims of MCDA methods is to enable 
decision makers to reach a decision by facilitating them to increase their 
understanding of the problem, objectives, and values being faced, through organising 
and synthesising information of complex and conflicting nature (Belton & Stewart, 
2002). MCDA can facilitate decision making by explicitly integrating objective 
measurement with value judgement while managing subjectivity in a transparent way, 
however it cannot act as a substitute to decision-making.  
Having introduced the theoretical foundations of decision analysis and the 
overall MCDA process, the next step is to focus on the model-building phase by 
applying MCDA principles. As part of the model-building phase, the criteria selection 
stage is crucial. This involves the identification and assembly of criteria into a 
hierarchical structure taking the form of a tree (Berkeley & Humphreys, 1982; von 
Winterfeldt & Fasolo, 2009). The aim is to arrive at a generic value model for new 
medicines that can be adapted to capture all relevant dimensions of value across 
different decision-making contexts and therapeutic indications. Criteria represent the 
key concerns influencing a particular decision. Structuring all criteria in the form of a 
tree is known as a value tree and provides an organized schematic representation of 
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the various concerns under consideration by the decision-maker. The criteria-based 
evaluation of options is operationalised through the use of performance descriptors, 
either of a qualitative or quantitative nature, known as attributes, which essentially 
measure the fulfillment of the criteria (Box 1). 
 
Box 1: Definitions of decision analysis terminology 
 
 
 
 
 
 
 
 
 
 
3. Methods 
3.1 Model building approaches  
The three main steps in building a multi-criteria model are to (a) structure a value tree 
that identifies and represents the objectives or key concerns of decision makers, (b) 
define attributes at the bottom level of the value tree to measure the achievement of 
these objectives, and (c) select decision alternatives (Franco & Montibeller, 2010).  
Structuring a value tree can generally be done using two approaches; either 
through a top-down approach (known as value-focused thinking), which is driven by 
the overall objective or value concern and is decomposed into lower levels of sub-
objectives or sub-concerns; or a bottom-up approach (known as alternative-focused 
Criterion: an ‘individual measurable indicator’ of a key value dimension (Department for 
Communities and Local Government, 2009) or more precisely, a ‘particular perspective 
according to which alternative technologies may be compared (Belton & Stewart, 2002).  
Attribute: a ‘quantitative or qualitative measure of performance associated with a particular 
criterion’ (Belton & Stewart, 2002), or in other words a descriptor of performance or impact  
requiring ordering of preference (R. Keeney, 1992). 
Value tree: an organized schematic representation of the various objectives, criteria and 
attributes under consideration. 
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thinking), which is driven by the alternative options under consideration based on 
attributes used to distinguish between them and which are grouped into higher levels 
of objectives and concerns (von Winterfeldt & Edwards, 1986).  
Given the aim of the study is to build a generic model that can subsequently be 
adapted and applied across different decision-making contexts, we used the top-down 
approach (value-focused thinking) (R. Keeney, 1992), so that the model can reflect 
the overall value concerns of decision makers while being adaptable to different 
decision problems. In other words we aimed to incorporate the value dimensions of 
new medicines that decision makers want to capture as part of the evaluation process.  
With regards to the completion of the remaining two tasks (attribute definition and 
selection of decision alternatives), we recommend the adoption of the bottom-up 
approach (alternative-focused thinking) following the definition of the decision 
problem (Buede, 1986), so that the model can become decision-specific to precisely 
assess the performance of alternative treatments as needed. As such, we suggest the 
completion of the two tasks and the model building process as part of particular 
applications, where the comparison of actual decision options feeds into the selection 
of precise attributes for distinguishing their value.  
Overall, in order to complete the three main steps, we have proposed a “value-
alternative hybrid thinking” (Angelis & Kanavos, 2016b), under which the core 
structure of the value tree takes place as part of a top-down approach, and the 
definition of attributes is ultimately completed following the selection of the decision 
alternatives as part of a bottom-up approach.  
Importantly, both criteria and attributes of the value tree must possess a 
number of properties for the results to be robust (Angelis & Kanavos, 2016b); these 
include being essential, non-overlapping and concise (for the case of criteria); 
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unambiguous, comprehensive and direct (for the case of attributes); understandable, 
operational, and preference-independent (for both criteria and attributes) (Belton & 
Stewart, 2002) (Franco & Montibeller, 2010; R. Keeney & Raiffa, 1993; R. L. 
Keeney & Gregory, 2005). A discussion on these properties as well as the 
significance of adhering to them in the context of HTA to ensure a robust process for 
the application of MCDA is provided elsewhere.  
 
3.2 HTA adaptation process and staging 
In the context of HTA, it would be reasonable to assume that the value concerns (i.e. 
the criteria) of decision-makers would encompass all key factors that are necessary for 
a comprehensive appraisal of value of a new medicine or health care intervention, 
with their relevant characteristics and impacts acting as descriptors of performance 
(i.e. attributes) for measuring the extent of satisfying these criteria. However, a 
universal or common set of decision-makers’ value concerns (i.e. criteria) and their 
measures (i.e. attributes) are neither clearly defined, nor well-established, both within 
and across health systems. Therefore, a definition of value in the context of HTA is 
currently absent (Angelis et al., 2017; Antoñanzas et al., 2016).  
In order to capture different decision-makers’ concerns in a comprehensive 
manner that ultimately would lead to the structuring of a generic value tree, a five-
stage iterative model-building process was followed, involving both secondary and 
primary data collection and adopting a top-down ‘value-focused thinking’ approach. 
The five steps were as follows, as shown in Figure 1: 
 
< Figure 1 about here > 
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Firstly, we conducted a systematic review of the peer-reviewed literature to 
identify what value dimensions are considered in the evaluation processes of HTA 
bodies in eight EU countries  (Angelis et al., 2017). The Centre for Review and 
Dissemination guidance for undertaking systematic reviews in health care was 
followed (Centre for Reviews and Dissemination, 2009). A flow diagram of the 
literature review process is shown in Figure 2. The eight study countries (and their 
HTA bodies) were France (Haute Autorité de Santé, HAS), Germany (Institut für 
Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG), Sweden (Tandvårds- 
och läkemedelsförmånsverket, TLV), England (National Institute of Health and Care 
Excellence, NICE), Italy (Agenzia Italiana del Farmaco, AIFA), the Netherlands 
(Zorginstituut Nederland, ZIN (formerly College voor zorgverzekeringen, CVZ)), 
Poland (The Agency for Health Technology Assessment and Tariff System, 
AOTMiT) and Spain (Red de Agencias de Evaluación de Tecnologías Sanitarias y 
Prestaciones del Sistema Nacional de Salud (RedETS) and the Inter-ministerial 
Committee for Pricing (ICP)).The rationale for their selection was the variation in 
their health system financing (tax-based vs. social insurance-based), the organisation 
of the health care system (central vs. regional organisation), the type of HTA in place 
(predominantly economic evaluation vs. predominantly clinical benefit assessment) 
and the perspective used in HTA (health system vs societal), so that the sample is 
representative of different health systems and HTA approaches across Europe. 
Inclusion criteria for the review were the following: (i) English language, (ii) 
evidence from the eight study countries of interest (and their respective agencies), (iii) 
HTA context from a national coverage perspective, and (iv) a publication date 
between January 2000 and January 2014; product-specific technology appraisals or 
evaluation studies and conference proceedings or records with no abstract available 
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were excluded. The electronic databases of Medline and Social Science Citation Index 
were searched for English peer review literature using the keywords “health 
technology assessment” OR “value assessment” AND “pharmaceuticals” OR 
“methodologies”. Reference lists of the selected studies were screened, and the HTA 
bodies’ websites were searched for any published guidelines. Material on the “type of 
evidence and evaluation criteria considered in HTAs” was collected and analysed, 
along with material on the “responsibilities and structure of national HTA models and 
processes”, “methods and techniques applied in HTA”, and “outcomes and 
implementation of HTAs”. The identified value dimensions sourced from the 
“evidence and evaluation criteria” component of the review would form the 
fundamental domains of the model, taking the form of top-level criteria groups (i.e. 
clusters) and informing their decomposition into lower level criteria, which comprised 
the core structure of the value tree.     
 
<Figure 2 about here> 
 
Secondly, literature findings were supplemented with expert consultation, 
where national agency HTA experts from the countries of interest where invited to 
review and validate the results. This took place because, upon early communication of 
the preliminary results with the partners of the Advance-HTA project consortium 
(Advance-HTA, 2013), it became obvious that in a few cases the evidence from the 
peer review literature may have been outdated and, in some cases contradictory, and 
did not reflect actual practices. As a result, the findings of the systematic literature 
review were validated with national experts from the agencies in question.  
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Thirdly, we incorporated findings from other relevant literature on health care 
intervention evaluation, including grey literature, to identify value concerns of 
decision makers that might not be reflected as part of the current or formal HTA 
evaluation criteria in place. We considered studies on the benefit-risk assessment of 
new drugs from a licensing perspective (EMA, 2007, 2008, 2011, 2012; FDA, 2005; 
Filip Mussen et al., 2007a; F Mussen et al., 2009; Filip Mussen et al., 2007b; L. 
Phillips et al., 2011; Walker et al., 2009), value based pricing and assessment from a 
payer perspective (DH, 2010, 2011; Miners et al., 2013a; Miners et al., 2013b; NICE, 
2011, 2014a, b; OHE, 2011), and patient access from a social responsibility 
perspective (Belgian Presidency, 2010; Working Group on Mechanism of 
Coordinated Access to Orphan Medicinal Products, 2012, 2013). The findings from 
this step supplemented the lower level criteria and their decomposition into bottom-
level sub-criteria or attributes. 
In the penultimate, fourth stage the emerging structure of the value tree and its 
criteria were subjected to a detailed consultation with 28 HTA experts who provided 
feedback on the comprehensiveness of the model, but also on its perceived usefulness 
and practical limitations, as part of the Advance-HTA project (Advance-HTA, 2013). 
These experts were selected because they acted as partners, Scientific Advisory Board 
members and affiliated scientists of the Advance-HTA project and included health 
care professionals (e.g. clinicians, nurses, pharmacologists), methodology experts 
(e.g. health economists, HTA experts, statisticians) patient representatives and policy-
makers/regulators, who were affiliated with a wide range of academic and research 
institutions at international level, including nine academic-research institutions with 
health economics and/or HTA centers, four HTA bodies, one HTA research network, 
one coordinating patient and health care professional organisation and one 
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international public health organization (see Appendix 1). Based on the feedback 
received from these experts, the structure of the value tree was revised in an iterative 
manner, mainly informing the bottom-level sub-criteria or attributes.  
Finally, following a series of dissemination activities involving presentations 
and seminars as part of capacity building workshops, feedback was collected from a 
wide range of stakeholders (mainly decision-makers from ministries of health, health 
insurance organisations and HTA agencies) and key opinion leaders across settings 
beyond the eight countries identified originally, where the aim was to validate results 
and further enhance the encompassing nature of the model by capturing additional 
expert and wider geographical perspectives (Angelis & Kanavos, 2014, 2015; 
Kanavos & Angelis, 2014, 2015). Specifically, the value tree was disseminated at four 
workshops attended by a total of 230 participants from the Latin American 
(November 2014 and September 2015) and Eastern European regions (September 
2014 and 2015), in order to capture perspectives from low-income and middle-income 
countries in these regions, in the form of smaller focus groups of 10-15 participants. 
Throughout the five stages of the model-building process, the various pieces 
of evidence collected to inform criteria selection and their structuring into a value tree 
took place in alignment with decision theory principles, aiming to satisfy the required 
criteria properties so that the model produced is rigorous and the analysis outcome 
robust (Franco & Montibeller, 2010). For example, an additional criterion would be 
added if a value concern was not captured in the initial set of criteria so that all the 
essential value concerns of decision makers could be addressed. Further, if a 
particular criterion was perceived to reflect the same value concern as another 
criterion, one of them was removed in order to avoid double counting. Similarly, two 
individual criteria could be replaced if their underlying concern could be reflected 
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from a single criterion on the basis of conciseness; generally, only the smallest 
number of criteria required for evaluation should be included, in order to strive for 
simplicity. Individual criteria could be replaced with other criteria if their meaning 
was not clear in order to improve comprehension; similarly, individual criteria would 
be replaced if their measurement was not possible, in order to ensure high levels of 
function. Finally, if by assessing the value of one criterion it became evident that 
knowledge on the performance of another criterion would be required, the two criteria 
would be aggregated into a single one in order to avoid preference-dependence.  
Despite this cautionary approach, the value tree aims to capture a 
comprehensive generic set of value concerns that can be adapted to different decision-
making contexts, problems, indications or treatments. As a result, following the 
completion of the model-building phase involving the precise attribute definition and 
the selection of alternative treatment options for the case of specific decision 
problems, some of these criteria might not satisfy the required properties, in which 
case the underlying issues should be addressed with caution. For example, following 
the operationalisation of two criteria with specific attributes it might become evident 
that there is possible double-counting between them, in which case one of the two 
would have to be excluded. A few cases in which the theoretical properties of some 
criteria could be put into question have emerged following consultation with experts; 
these are discussed in the respective sections.  
Overall, the five-stage process took place between February 2013 and end-June 
2016.   
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4. Results - The Advance Value Tree  
We briefly present the findings from the systematic literature review and expert 
consultation in HTA, which acted as the first stage of the model-building process, 
mainly because it informed the primary identification of value dimensions which 
established the core structure of the value tree. Then we outline the completed value 
tree and discuss the logic behind its various components and value dimensions, 
including the overall criteria grouping and decomposition from top-level criteria 
clusters into lower level criteria and bottom level sub-criteria or attributes. Finally, we 
briefly suggest how to deal with quality of evidence, and more precisely with clinical 
validity concerns, using penalty functions.   
 
4.1 Primary identification of value dimensions: findings from the systematic 
literature review and expert consultation in HTA 
In total, 2778 article abstracts were screened. Out of these, 255 articles were selected 
to be read in full due to their relevance and 101 articles were ultimately used. The 
main groups of value dimensions that were found to be considered as evaluation 
criteria among the study group of European countries, identified through the first 
stage of the model-building process included: (a) burden of disease, (b) therapeutic 
impact, (c) safety profile, (d) innovation level, (e) socioeconomic impact, (f) 
efficiency considerations, and (g) others (Angelis et al., 2017). Individual value 
dimensions falling under the first five groups of evidence (a – e), together with their 
intensity of use by each country are shown in Table 1; efficiency considerations and 
other types of concerns were excluded because they would contradict the necessary 
theoretical properties of criteria as explained below. Based on the available evidence, 
these five clusters of value dimensions were perceived to comprise the critical aspects 
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of value concerns to decision makers for evaluating the value of new medicines as 
part of HTA, providing the core foundation of the value tree.  
 
<Table 1 about here> 
 
4.2 Incorporating the value dimensions into a generic model: The Advance Value 
Tree  
Ultimately, the resulting generic value tree spans three levels of evaluation criteria 
(top-, middle- and bottom-level), where top-level groups of criteria (i.e. criteria 
clusters) are decomposed into middle-level criteria and bottom-level sub-criteria or 
attributes, relating to the five key value domains described above that can be 
explicitly measured and assessed: (a) burden of disease (BoD), (b) therapeutic impact 
(THE), (c) safety profile (SAF) (d) innovation level (INN), and (e) socioeconomic 
impact (SOC). With the exception of the BoD cluster, which relates to the disease or 
indication of interest, the remaining four clusters relate to the impact or characteristics 
of the medicine. The hierarchical representation of the three levels of evaluation 
criteria forms the different components of the value tree, which we called ‘Advance 
Value Tree’ (Figure 3).  
 
<Figure 3 about here> 
 
Although additional types of value concerns might exist falling under other 
categories (Guindo et al., 2012; Mirelman et al., 2012; Tanios et al., 2013), such as 
efficiency (e.g. cost-effectiveness), equity (e.g. priorities, fairness, ethics, etc.) and 
implementation complexities (e.g. organisational, skill and legislative requirements), 
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they are not included as criteria because they would contradict with the desired 
criteria properties and the adopted scope of “value”. These dimensions do not 
represent intrinsic but, instead, extrinsic characteristics that mostly depend on the 
value tree’s core variables, or other features of the health care systems reflecting a 
health system’s goals and building block perspective (Tromp & Baltussen, 2012).  
For example, efficiency is a composite concept comprising two components, 
i.e. cost and benefit, with the latter already reflected in the model and thus its 
inclusion would violate the principle of non-overlap leading to double-counting. 
Concerns relating to equity, implementation complexities, and other characteristics of 
the overall health systems’ context (e.g. stakeholder pressure and political power), are 
usually of subjective nature and not easily quantifiable, therefore making it hard to 
operationalise. All these extrinsic value dimensions do not relate to the “value” of a 
new medicine per se, but instead depend on the settings of the particular health 
system under consideration. They could therefore be considered or incorporated on an 
optional and as needed basis for the particular decision context and problem in 
question, possibly through the application of other analytical frameworks in parallel 
(EUnetHTA; Mireille M. Goetghebeur et al., 2008b). 
Examples of iterations in the value tree that have resulted from consultations 
with experts include the aggregation of ‘safety’ and ‘tolerability’ criteria into a single 
‘safety & tolerability’ criterion when a potential overlap between their measures 
became evident following discussions with clinicians (described in the ‘Safety profile’ 
section below), or the addition of a ‘Carer’ sub-criterion under the ‘Indirect costs’ 
criterion to capture the wider socioeconomic impact of a treatment following 
discussion with patients.  
 
24 
 
4.2.1 Burden of Disease 
‘Burden of Disease’ (BoD) forms a special set of value dimensions as they do not 
relate to the medical technology itself, but to the disease it is indicated for and, as 
such, could encompass the severity and unmet need of the disease the treatment 
addresses (Linley & Hughes, 2013; Miners et al., 2013a). Severity of the disease 
relates to the condition’s degree of seriousness in respect to mortality and morbidity-
derived disability, which could be defined on the basis of disability-adjusted life years 
(DALYs) lost (Murray & Lopez, 1996), or the expected remaining life years adjusted 
for their quality of life (Hansson et al., 1994). Unmet need reflects the availability of 
treatments, essentially the degree to which there are existing treatments (DH, 2010) 
and could relate to methods of diagnosis, prevention or treatment (EC, 2006). Because 
these dimensions are preference-dependent (i.e. in order to assess the impact of unmet 
need one needs to consider the severity of the disease) they are operationalised 
through the use of a single aggregated attribute which could be defined as the gap 
between the health status that patients with a particular medical condition can attain 
using existing medical interventions and the health status they could expect if they did 
not have that medical condition, or in other words “the number of QALYs lost by a 
patient because of their condition” (Miners et al., 2013a), i.e. unmet need gravity 
attribute. Therefore, the BoD attribute reflects the difference in the years of life 
remaining (adjusted) with the respective health-related quality of life (HRQoL) for 
patients receiving existing technologies, versus the years of life remaining (adjusted) 
with the respective HRQoL for healthy individuals (of the same age). The larger the 
difference or the gap between the two (i.e. diseased vs. healthy states), the higher the 
disease burden. It should be noted that ideally the “existing” medical intervention or 
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treatment should not be one of the options being assessed so that there is no double 
counting with the Therapeutic Impact cluster. 
The size of the population being affected by the disease, and the possible 
differentiation of a disease on the grounds of high prevalence or low prevalence, is 
not taken into account because it could be perceived as unethical. The justification of 
a special status of a disease based on its prevalence would be questionable, as it 
entails valuing one disease differently to another because they are a more common vs. 
a less common disorder (McCabe et al., 2005). The only justification for providing 
special status to rare diseases would be on equity grounds, using the rationale that 
“patients suffering from rare conditions should be entitled to the same quality of 
treatments as other patients” (European Parliament, 2000). However, this concern is 
already addressed through the unmet need criterion and the associated (un-) 
availability of effective treatments; consequently, the inclusion of a criterion for 
capturing ‘population size’ would essentially lead to double-counting and, therefore, 
is not inserted. Valuing a condition ‘more’ or ‘less’ as a result of prevalence would be 
incompatible with other equity principles and theories of justice (McCabe et al., 
2005).  
 
4.2.2 Therapeutic Impact 
For most medical conditions there is a set of multidimensional health outcomes that 
need to be jointly used to capture overall patient benefit including survival, functional 
status, sustainability of recovery and others, including complications (Porter, 2010). 
Outcomes are distinct from biologic indicators, the former relating directly to health 
status in contrast to the latter which acts as predictor of results.  
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The ‘Therapeutic impact’ cluster captures clinical benefit by measuring both 
direct outcomes and indirect indicators relating to the efficacy and/or the effectiveness 
of an intervention with the view to reflecting the health status but also disease 
recovery, progression or prevention (complication outcomes are considered separately 
in the “Safety Profile” cluster discussed in the next section).  
In order to distinguish between the difference in direct outcomes and indirect 
indicators, based on both the literature and following expert consultation “Therapeutic 
Impact” criteria have been divided into (a) direct, clinically meaningful endpoints and 
(b) indirect, surrogate endpoints respectively; the latter are used as substitutes for 
direct endpoints, and are usually disease-specific in nature (e.g. HbA1c for 
complications in diabetes mellitus, prostate-specific antigen (PSA) for prostate 
cancer, blood pressure for cardiovascular disease). Specifically, a direct endpoint is 
defined as a “characteristic or variable that reflects how a patient feels, functions, or 
survives” while an indirect endpoint is defined as a “biomarker intended to substitute 
for a clinical endpoint” which is “expected to predict clinical benefit (or harm or lack 
of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other 
scientific evidence” (Biomarkers Definitions Study Group, 2001) (page 91); in turn, 
the definition of a biomarker states that it is a “characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” (Biomarkers 
Definitions Study Group, 2001) (page 91). However, both types of endpoints are 
useful and, for specific indications, a biomarker, (i.e. indirect indicator) might be 
more directly related to real health status than self-reported outcomes (i.e. direct 
outcome). Below we propose a further decomposition of direct meaningful endpoints 
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and indirect surrogate endpoints, once again guided by the five-stage evidence 
collection process.  
Direct meaningful endpoints 
Direct clinically meaningful endpoints can be divided into objective and subjective 
endpoints (Sullivan) and, possibly, other health related outcomes (Spahn, 2003). 
Objective direct endpoints mainly refer to survival, disease exacerbation/alleviation 
and clinical events. The availability of evidence on different endpoints depends on the 
study designs adopted by the respective clinical trials for evaluating the clinical 
benefit of interventions and, therefore, would depend on their type or nature.  
Subjective direct endpoints mainly relate to HRQoL and disease symptoms. 
HRQoL embraces the broader concept of health that includes physical, emotional and 
social wellbeing (World Health Organisation, 1948), by including both personal 
health status and social wellbeing (G. H. Guyatt et al., 1993) which are usually  
“subjectively” assessed through patient reported outcome measures (PROMs). 
HRQoL is multidimensional (Chen et al., 2005) (Cherepanov et al., 2010) and can 
generally be measured through the use of generic PROMs that provide a summary of 
HRQoL attributes through the production of health utilities (G. H. Guyatt et al., 
1993), such as SF-36 and EQ-5D instruments. Generic PROM instruments do not 
target specific population groups and for the case of particular disease states they 
might not be sensitive enough to adequately capture the impact across all HRQoL 
dimensions in which case disease specific instruments might be needed. From a 
societal perspective all of these dimensions should be considered both for the cases of 
patients and carers.   
Importantly, following consultation with experts, it became apparent that the 
assessment of particular combinations of objective and subjective endpoints as, for 
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example, overall survival (OS) and HRQoL (e.g. through EQ-5D) might be preference 
dependent. For example, in the context of a metastatic cancer setting, stakeholders 
highlighted that their preferences related to the performance of different therapies in 
terms of OS would be meaningful only if the HRQoL performance was also known 
for the same therapies. Where preference dependence is evident, the dependent 
attributes should be combined into a single attribute, as for example QALYs, 
essentially aggregating them into a common attribute capturing both OS and HRQoL 
considerations. 
Indirect surrogate endpoints 
Indirect surrogate endpoints can be divided into validated and non-validated. 
Validation of a surrogate endpoint is the process of retrospectively linking it to the 
actual clinical endpoint (or outcome), i.e. demonstrating a relationship between the 
two by evaluating how well the surrogate endpoint predicts the clinical outcome of 
interest (Biomarkers Definitions Study Group, 2001). Over and above the existence of 
a strong statistical correlation between the surrogate and the clinical endpoint that is 
required in order to attain an accurate prognosis of the clinical outcome, i.e. 
“individual-level surrogacy”, there is also a prerequisite for clinical correlation 
through the existence of biologic plausibility, i.e. scientific evidence on the causality 
between the disease, surrogate and outcome; importantly, there is also a need for 
demonstrating “trial-level surrogacy” which refers to the correlation between a change 
in the surrogate and a change in outcome due to a therapeutic intervention (Buyse et 
al., 2000). Although trial-level data are usually coming from multiple trials or units 
for the same type of intervention, for a surrogate to be validated it means that its 
“validity is generalizable to include other interventions that affect the surrogate 
endpoint” (Biomarkers Definitions Study Group, 2001) (page 93). As a result of these 
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requirements, surrogate endpoints are rarely validated. Generally, most only just 
manage to predict the clinical endpoint or outcome of interest whilst others fail to 
predict the clinical endpoint and are used simply as a measure of biological activity 
(Fleming, 2003).  
 
4.2.3 Safety profile 
The safety profile of an intervention comprises information relating to the degree of 
its safety and toxicity for the indicated patient population of interest. It is usually 
measured through safety and tolerability but can also be reflected through any contra-
indications for its use and special warnings (and precautions) for any particular sub-
populations.  
Safety and tolerability 
Safety has been traditionally reflected through the incidence of adverse events. An 
adverse event (AE) refers to an adverse outcome occurring when a drug is 
administered to a patient or at some time afterwards, in which case the drug might or 
might not be the cause of the AE (Aronson & Ferner, 2005). If such outcomes can be 
attributed with some degree of probability and through a causative link to an action of 
the drug, then they are known as adverse drug events (ADEs).  
The magnitude of both AEs and ADEs is measured through the combination 
of their seriousness and their frequency (or probability of taking place). Given that 
seriousness and probability of adverse events seem to be preference dependent, an 
aggregated attribute reflecting ‘seriousness and frequency’ would be needed. 
Seriousness could be operationalised through the use of the Common Terminology 
Criteria for Adverse Events (CTCAE) classification, which contains five grades of 
adverse events ranging from mild (Grade 1) to death (Grade 5), with three grades in 
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between (moderate, severe, life-threatening) (Institute, 2009). However, for cases that 
OS is already incorporated in the value tree under the therapeutic impact cluster, then 
considering Grade 5 adverse events which relate to deaths would constitute double 
counting and should be excluded. In turn, given that the distinction of adverse events 
between mild and moderate and between severe and life-threatening is often 
subjective, they could be aggregated and categorised as “non-serious” versus 
“serious”, the former comprising Grade 1 and 2, and the latter comprising the Grade 3 
and 4 adverse events. Frequency could be operationalised through the use of absolute 
incidences (percentages), or, alternatively, using a frequency classification system 
such as the Naranjo scale which expresses frequency in terms of definite, probable, 
possible or doubtful (Naranjo et al., 1981).  
Tolerability refers to the overall ability of the patient to tolerate the 
intervention, mainly in regards to bearing and enduring any adverse events. It is 
usually reflected through the variables of treatment discontinuation and treatment 
interruption or reduction, measured either as the proportion of patients discontinuing 
the treatment (or interrupting/reducing its dosing) or the time to treatment 
discontinuation (TTTD) from the treatment.  
Importantly however, as became apparent following consultation with clinical 
experts, in the case of discontinuation (or interruption or reduction) of a treatment 
being due to the incidence of known ADEs, then incorporation of both measure types 
could lead to double-counting and therefore caution would be needed to ensure the 
most appropriate of the two criteria was chosen for inclusion.  
Contraindications, special warnings and precautions 
Contra-indications refer to, usually risk and safety, factors that act as a reason for an 
intervention to not be used by a patient, which therefore has an impact on the number 
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of potential patients using and benefiting from the intervention. Strictly speaking, 
contraindications can be categorised as absolute and relative. In the former 
categorization there are no circumstances under which the patient might use the 
intervention, compared to the latter where the risk might be outweighed in favour of 
other considerations (e.g. x-rays for a pregnant woman with a risk of having a child 
with birth defects). Special warnings and precautions for use are designed with the 
view to notifying potential risks associated with the use of the intervention in regards 
to specific patient sub-populations with particular characteristics. These 
characteristics mainly relate to the administration of concomitant medication, the 
coexistence of other accompanying diseases and the presence of idiosyncratic patient 
pathological features that, as a result, might influence the expected action of the drug; 
as a consequence, caution in the form of careful monitoring is usually suggested.  
In the real world, some patients with known contra-indications (or special 
warnings and precautions) for a treatment may receive it, in which case incorporation 
of any evident ADEs or tolerability consequences that can be related to them as 
attributes in the value tree, would lead to double counting between the two and should 
therefore be addressed with caution, similar to the case between ADEs and 
discontinuation.  
 
4.2.4 Innovation Level 
 “Innovation” in the context of medical technologies, ranging from 
biopharmaceuticals and diagnostics to medical devices, is a complicated concept 
lacking a universal consensus (Kesselheim et al., 2013).  From a patient perspective, 
“innovation” mainly relates to “therapeutic innovation” requiring novelty of 
effectiveness: value needs to be created by generating improved health outcomes that 
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were previously unattainable, the degree of which could be assessed through the 
combination of the significance of the unmet medical need the drug addresses and the 
extent to which it improves the health outcomes for that need (Morgan et al., 2008).  
Below we discuss secondary innovation dimensions over and above 
“therapeutic innovation”, given that the significance of unmet medical need and the 
extent of health outcomes improvement are captured under the “Burden of Disease” 
and “Therapeutic Impact” clusters respectively. These dimensions include (a) the 
mechanism of action, (b) the technology’s spillover effects, and (c) patient usefulness 
(convenience). 
Mechanism of action 
The innovativeness of new medicines can be differentiated according to their type or 
nature, based on whether they offer a novel mechanism of action, or whether they act 
through more typical mechanisms of action. A relatively practical and objective way 
of measuring that would be through the use of WHO’s Anatomical Therapeutic 
Chemical (ATC) Classification System
1
.  In the ATC classification system, the active 
substances are divided into different groups according to the organ or system on 
which they act and their therapeutic, pharmacological and chemical properties.  
Moving from general to specific, drugs are classified in groups at five different levels 
relating to anatomical, therapeutic, pharmacological, chemical and molecular 
dimensions which could act as the respective criteria. The drugs are divided into 
fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd 
                                                 
1
 In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances 
are divided into different groups according to the organ or system on which they act and their 
therapeutic, pharmacological and chemical properties. Drugs are classified in groups at five 
different levels. The drugs are divided into fourteen main groups (1st level), with 
pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are 
chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. 
The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is 
considered more appropriate than therapeutic or chemical subgroups. 
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level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups 
and the 5th level is the chemical substance.  
By this logic, a medicine characterised by a novel therapeutic action, would be 
more innovative than a medicine with a novel pharmacological action and so on. In 
other words, the broader the level at which the drug (or combination) differentiates as 
‘original’ compared to current existing alternatives, the more innovative the nature of 
that drug (or combination) would be. As a result, the drug’s relative market entrance 
in regards to the different innovation subgroups (i.e. ATC levels) could act as the 
respective attributes, in order to reflect, for example, whether it is first-in-chemical-
class (i.e. first entrance of a technology at level 4, chemical subgroup level), second-
in-pharmacological-class (i.e. second entrance of a technology at level 3, 
pharmacological subgroup), and so on.  
Spill-over (dynamic efficiency) 
Any type of innovation can have R&D spill-over effects that can lead to the 
development of subsequent innovation(s), entailing a certain degree of diffusion of 
scientific knowledge and/or technical know-how. Innovation “spill-over effects” 
could be defined as “the R&D positive externalities that can lead to the development 
of subsequent innovation(s)”, thus essentially relating to dynamic efficiency in 
regards to long-term product innovation at future market conditions. These effects 
could take the form of internal (within the innovator) or external (outside the 
innovator) effects (OHE, 2005). As Lipsey and Carlow have argued, “major radical 
innovations never bring new technologies into the world in a fully developed form”, 
but “appear in a crude and embryonic state with only a few specific uses” (Lipsey & 
Carlow, 2000). Instead, successive improvements are accumulated through the 
processes of “learning by doing” and “learning by using” (Mestre-Ferrandiz et al., 
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2012), the former referring to the improvement of workers’ skills at the 
manufacturing level (Arrow, 1962), while the latter relating to enhancements of 
knowledge at the level of utilisation by the final user (Rosenberg, 1982). Subsequent 
to the market entry of a new drug, new uses (i.e. new indications) for the same drug 
could be uncovered following its investigation for use by patients with other diseases, 
or next generation drugs could be successively developed either for the same disease 
indication or a different one. New scientific knowledge and/or technical know-how 
could be diffused into other contexts/sectors, leading to innovations therein. Because 
the impact on future innovation is uncertain, it would be practically challenging if not 
impossible to be predicted and assessed at a single point in time (Rosenberg, 2001), as 
for example the rate at which performance improvements take place and the speed at 
which new uses are discovered. In reality, a significant portion of any such spill-over 
effects will need time to materialize requiring them to be in the market for a period of 
time.  
Although these effects can relate to new uses for the same technology, new 
technologies for the same use, or new technologies for new uses, only the first ones 
are considered here because the latter two are not operational. We choose to exclude 
the latter two because it would be very hard, if not impossible, to identify whether a 
new technology has been developed following the R&D process of another 
technology, hence establishing the causative link required would be challenging.  For 
example, for the case of a new technology developed by the same manufacturer of the 
parent technology, it could be the case that actually the later technology was the one 
that drove the development of the first technology, but delays in the regulatory 
processes caused one to be marketed before the other. Essentially, this criterion would 
refer to the extent to which the drug has a spill-over effect in the context of expansion 
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into new indications and could be operationalized by examining the number of new 
indications for which the drug is investigated at each stage of clinical development 
(e.g. Phase I, Phase II, Phase III, Marketing Authorisation phase).  
Patient usefulness (ease and convenience) 
Aspects relating to patient usefulness would be another group of innovation-related 
dimensions. The satisfaction of patients with medical care has been shown to correlate 
with compliance, i.e. the willingness and ability to follow health-related advice 
including adherence to prescribed medication, while also acting as a predictor of 
future compliance (Becker & Maiman, 1980; Nagy & Wolfe, 1984; Smith et al., 
1987). Satisfaction can be categorised into a range of different domains, including 
symptom relief/efficacy, side effects, ease and convenience, impact on HRQL, 
general satisfaction, and other domains specific to the given question (Shikiar & 
Rentz, 2004). Given that most of these domains are associated with the health 
outcomes of the treatment, or are of a generic nature, only ease and convenience are 
considered here, essentially relating to mode of administration, dosing schedule, 
medication restrictions, and product-specific designs. Poor compliance has been 
reported as the most common cause of non-response to medication, with evidence 
supporting that better health outcomes are produced when patients adhere to treatment 
recommendations compared to those who do not adhere (Murphy & Coster, 1997). 
Therefore, any improvements on the above can be translated into greater patient 
satisfaction and possibly better treatment compliance, which could lead to improved 
health outcomes, either through an increase in clinical effectiveness or due to a 
decrease in adverse events. In turn, individualising treatment and minimising its 
complexity has been proposed in order to encourage adherent behavior (O'Brien et al., 
1992); for example, once-daily dosing had been suggested as an important part of 
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enhancing compliance, patient convenience and regimen simplification in 
hypertension (Rudd, 1995), among others.   
Given that patient health outcomes are already incorporated in the value tree, 
it would be expected that it is necessary to assume an explicit disconnection between 
better patient satisfaction and improved health outcomes in order to avoid double-
counting. This theoretical rationality would support the notion that greater satisfaction 
through improved ease and convenience is a critical value dimension of new 
medicines in its own right, contributing to product novelty. Nevertheless, such a strict 
dissociation between satisfaction and health outcomes might not be required in the 
first place because of the gap between experimental efficacy data and real world 
effectiveness (see Appendix 2). 
Specific aspects of improved ease and convenience can include less invasive 
delivery systems, improved posology due to reduced dosing frequency or duration of 
administration and abolition of special administration instructions (e.g. no instructions 
vs. “take without food”). An altered delivery system could involve a change in dosage 
form (e.g. tablet, liquid, spray, gel) or a change in route of administration (RoA) (e.g. 
oral, subcutaneous, transdermal), but because these two variables are almost always 
correlated (e.g. a tablet will most probably administered orally, and a gel will most 
probably administered transdermally), both aspects could be captured through a 
common ‘delivery system’ attribute reflecting the combination of dosage form and 
RoA. Differences in posology could be captured by an attribute reflecting the 
combination of dosing frequency in a given time period and treatment duration of 
each dose. However, following consultation with patients it became apparent that in 
order to assess a treatment’s ‘posology’, one might need to consider the treatment’s 
‘delivery system’, therefore suggesting for preference dependence between the two. 
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As a result, the two types of value concern were aggregated into a common ‘delivery 
system and posology’ criterion. Special instructions could be assessed by an attribute 
reflecting the existence of any special instructions accompanying the administration 
of the treatment (e.g. once weekly vs. daily over 1 hour). Alternatively, the 
medication regimen complexity index (MRCI) could be used as an all-inclusive proxy 
attribute to operationalise the assessment of ease and convenience as it incorporates a 
number of medication regimen aspects, including dosage forms, dosage frequency and 
administration instructions (George et al., 2004). 
 
4.2.5 Socioeconomic Impact 
Socioeconomic impact dimensions are used to incorporate any other concerns or 
benefits in the wider context, which mainly relate to (a) public health and (b) 
economic considerations.  
Public health impact 
Public health impact is primarily associated with any risk reduction in transmitting 
and developing the disease under consideration or any other disease within the 
broader population, thus reflecting a societal dimension of prevention. The levels of 
risk reduction could range from no risk reduction, to reduction of prevalence risk 
factors, to reduction in transmission, to prevention and prophylaxis from the disease 
(Mireille M. Goetghebeur et al., 2008b), and as a result such a variable would be more 
applicable to the case of infectious diseases and diseases with known risk factors. The 
emergence and dissemination of resistance among pathogenic bacteria to the available 
antibiotics used in medical practice, leading to the latter’s drop in effectiveness, 
would be a good example. A hypothetical new class of antibiotics that can effectively 
treat a bacterial strain known to have developed antimicrobial resistance, would offer 
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an important risk reduction of the disease within the broader population by ‘dealing 
with resistance’ and inhibiting its transmission. The added value of such a drug would 
materialise through the combination of improved health outcomes (as reflected via the 
“Therapeutic impact” cluster) and through a risk reduction in disease transmission as 
reflected via the “Public health impact” dimension in the socio-economic impact 
cluster.  
Economic impact 
Economic impact dimensions reflect the economic burden of the disease and can be 
mainly divided into direct costs and indirect costs. Cost of illness studies are used to 
identify and measure all costs related to a particular disease and although different 
studies can employ different methodologies and designs they usually adopt a common 
classification of cost types (Hodgson & Meiners, 1982). Direct costs can be either 
medical or non-medical; medical costs are the costs resulting directly from the disease 
treatment and include diagnostic tests, prescription drugs, inpatient care (hospital or 
physician), outpatient care (physician or ER), nursing home care, rehabilitation care 
and home health care including any disposable or replacing items (e.g. prosthetic 
limbs). Direct non-medical costs refer to non-healthcare costs and include costs 
related to transportation, relocation, household, comfort/rehabilitation items, property 
alterations and counselling services.  
However, including ‘cost’ as a value dimension is prone to criticism, mainly 
because criteria should be conceived as attributes of benefit (K Claxton, 2013). For 
that reason “impact on costs” rather than absolute costs are considered, looking at the 
marginal difference versus an alternative option that could act as a neutral benchmark, 
being exclusive of the purchasing costs of the drug; this comparator could fall outside 
the scope of the analysis. For example, in the oncology setting where the chosen 
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comparator in question could be palliative care or best supportive care, rather than an 
active treatment. The purchasing cost of the options could be incorporated at a later 
stage of analysis to establish the efficiency of the technology by considering its total 
value in relation to its total cost.  
Indirect costs reflect productivity losses arising from patient absenteeism, 
presenteeism, premature retirement, and premature mortality (Zhang et al., 2011). In 
addition, as became evident following consultation with patients, indirect costs for 
carers (i.e. caregivers) are an important dimension of productivity losses that should 
be considered as part of a societal context and can relate either to financial costs (in 
case they are not already included in the medical and non-medical costs) or time-off 
work. 
 
4.3 Dealing with quality of evidence 
In the context of health care decision-making, several attributes related to evidence 
quality could be identified such as adherence to the requirements of the regulator or 
decision-maker, completeness of reporting according to the regulator’s guidelines, 
consistency of reporting with the sources cited, relevance of evidence to the context in 
question and validity of evidence in regards to scientific standards or methodological 
guidelines of research (M.M. Goetghebeur et al., 2008a).  
Focusing on the validity of clinical evidence, which would mainly be relevant 
for evidence feeding the performance measurement of alternative options under the 
therapeutic impact (THE) cluster, could be decomposed into internal and external 
validity characteristics. Internal validity refers to the extent to which an observed 
effect can be attributed to the intervention under investigation, or, in other words, the 
extent to which it is free from bias, in contrast to external validity which relates to the 
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generalisability of clinical effect from experimental settings to real world settings 
(CRD, 2008; Eldridge et al., 2008; Rothwell, 2006).  Rather than operationalising 
these evidence quality (i.e. validity) concerns through their incorporation as criteria 
and attributes in the value tree, ‘penalty’ functions could instead be applied when the 
clinical evidence used for the alternative options are of different quality. This is 
because it would not be methodologically robust to incorporate quality of evidence 
concerns as criteria; doing so would entail that the quality of evidence used to assess 
the performance of the options across the respective criteria could be compensated by 
the options’ performances across the same criteria, which is not rational.  
A penalty factor could be applied through a function that multiplies it with the 
performance of the alternative options across the relevant THE criteria or their 
respective value scores, in order to adjust them for their validity. This penalty factor 
would be tailor-made for the particular decision-making context, being defined based 
on the relative importance of evidence validity as a source of concern to decision-
makers. For example, assuming that a weak internal validity is associated with the 
comparative treatment effect of a new drug due to inadequate allocation concealment 
and lack of double-blinding, a “strict” decision-maker might be willing to “discount” 
the clinical performance of the drug on some of its clinical endpoints up to 50% of 
their original level. The lower the validity of the evidence, the higher the impact the 
penalty functions would have on the performances of the drugs or their respective 
value scores across the relevant THE criteria. However it should be noted that the 
concept of penalty function should generally be used with caution as they may be 
incompatible with the use of an additive value model (unless they are used within the 
attributes).  
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A useful categorisation for the quality of clinical evidence is provided by the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
system, a framework developed for the purpose of producing consistent clinical 
guidelines in terms of rating quality of evidence and grading strength of 
recommendations (Gordon H. Guyatt et al., 2008). According to GRADE, high 
quality evidence could be defined as evidence for which “further research is very 
unlikely to change our confidence in the estimate of effect”, in contrast to very low 
quality evidence for which “any estimate of effect is very uncertain”. In turn, the 
Cochrane Collaboration tool for risk of bias and the RE-AIM framework could be 
applied for the assessment of internal and external validity respectively, the findings 
of which could then be used for the estimation of the penalty factor by feeding the 
penalty function.  
Based on a systematic classification of internal validity sources, the Cochrane 
Collaboration has developed a tool for assessing the risk of bias in RCTs, for a series 
of items covering different bias domains and their sources (Higgins et al., 2011). 
These bias domains are broken down into seven different types based on which RCTs 
can be assessed and rated (as “low”, “unclear” or “high” risk of bias), namely 
selection bias (with sources of bias including random sequence generation, and 
allocation concealment), performance bias (blinding of participants and personnel), 
detection bias (blinding of outcome assessment), attrition bias (incomplete outcome 
data), reporting bias (selective reporting) and other bias (i.e. anything else).  
On the other hand, the RE-AIM framework which was originally developed by 
Glasgow and colleagues to evaluate the public impact of health interventions, could 
be partially applied in order to assess the external validity of clinical trials, mainly 
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through the dimensions of reach, adoption, implementation and maintenance 
(Glasgow et al., 1999). 
 
5. Discussion  
5.1 Robustness of the Advance Value Tree 
In this paper we developed and proposed a generic model taking the form of a value 
tree for assessing the value of new medicines in the context of HTA as part of a 
methodological approach, which moves away from traditional economic evaluation, 
uses decision theory and adopts multi-criteria evaluation methods. Our model consists 
of a value tree (Advance Value Tree) with three levels (top-level: 5 clusters; middle-
level: 11 criteria; bottom-level: 28 sub-criteria or attributes), as shown in Figure 3. 
Conceptual and theoretical advantages emerge from the methodological and 
empirical process that was adopted to build the structure of the Advance Value Tree. 
A five-stage iterative model-building process was followed involving extensive 
rounds of literature reviews and expert consultation, with the aim of making it as 
comprehensive as possible, whilst maintaining its flexibility and adaptability to serve 
the needs of decision-makers for different decision-type problems. A key advantage 
of the Advance Value Tree is its strong alignment with decision theory principles, 
adopting a top-down value-focused thinking approach while paying attention to the 
required criteria properties.  
  For the case of specific decision problems and following the selection of 
particular treatment options, the value tree could be adapted using a bottom-up 
approach in order to capture the particular value dimensions of the actual treatment-
indication pairs. This would involve the definition of precise attributes, which should 
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again take place in alignment with decision theory principles and would complete the 
model-building phase of the process. 
Following the model-building phase, model-assessment and model-appraisal 
phases need to be completed. As part of this the model can be estimated by applying 
different types of MCDA modelling techniques for the formation of value judgements 
and elicitation of preferences across the options. 
 
5.2 MCDA Methods and Selection of Modelling Techniques to Operationalise the 
Advance Value Tree 
Multiple MCDA methods exist of varying complexity that could be used for the 
estimation of the model. Specifically, an MCDA modelling technique is required for 
expressing preferences on the performance of each option against each criterion 
(scoring), while equating the preference units across all criteria (weighting), and 
combining preferences of individual criteria together into a combined overall 
preference (aggregating). Therefore, “modelling” in this context acts as an instrument 
for enabling decision-makers to understand their own preferences, by helping them to 
construct their perceptions given a set of assumptions, as part of the overall process of 
identifying the best decision (Belton & Stewart, 2002).  
Among the plurality of existing MCDA approaches, they could be categorized 
into three main groups of methods governed by different “schools of thought”, 
notably (a) value measurement methods, including multi-attribute value theory 
(MAVT) and multi-attribute utility theory (MAUT) methods, (b) outranking methods, 
and (c) ‘satisficing’ and aspiration level methods as suggested by others (Belton & 
Stewart, 2002; Department for Communities and Local Government, 2009; Hammond 
et al., 1999; von Winterfeldt & Edwards, 1986). These three main groups of methods 
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essentially relate to different classifications of preference modelling. Other 
classifications have also been proposed as there is no consensus on a universal 
categorization (Diaby & Goeree, 2014; Dolan, 2010; Goodwin & Wright, 1997; 
Thokala & Duenas, 2012).  
The methodological process we have proposed pertains to the value 
measurement methods category (Angelis & Kanavos, 2016b), mainly because of the 
multiple decision contexts that it can be applied to and the simplicity of the value 
judgements required (in addition to limited restrictions imposed by the axioms 
employed), features which would probably influence their adoption into the most 
widely used MCDA methods in health care (Marsh et al., 2014).  Specifically, we 
argue in favour of MAVT methods because of their comprehensiveness and 
robustness (von Winterfeldt & Edwards, 1986), as well as their ability to reduce 
ambiguity and motivational biases. We would therefore suggest the operationalisation 
(i.e. estimation) of the Advance Value Tree through such a MAVT approach. This is 
also consistent with recent work on good practices for MCDA in Health Care 
Decisions (Marsh et al., 2016). Yet, the value tree and the incorporated criteria 
clusters could also be operationalised through other MCDA methods that go beyond 
the value measurement category (Guitouni & Martel, 1998). 
With MAVT methods, value functions for the scoring of the options can be 
elicited in different ways,  mainly by using direct or indirect rating techniques (Belton 
& Stewart, 2002; von Winterfeldt & Edwards, 1986). In contrast to direct rating 
techniques, indirect techniques aim to uncover decision makers’ preferences indirectly 
through a series of questions that involve differences in the attribute scale and their 
relation to the value scale, producing a transparent valuation relationhsip across the 
complete attribute range, rather than limited to the perfomance of the options under 
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consideration. Techniques that explore the magnitude of increments in the attribute 
scale that yield equal units in the value scale are known as indifference techniques, 
whereas techniques that estimate points on the attribute scale that act as midpoints on 
the value scale are known as bisection techniques; both of these could be regarded as 
sub-types of indirect techniques. An alternative indirect approach would be 
“Measuring Attractiveness by a Categorical Based Evaluation Technique” 
(MACBETH) which considers pairwise attribute comparisons (Bana E Costa et al., 
2012; Bana e Costa & Vansnick, 1994). In MACBETH value functions are elicited 
through comparison of two attribute levels at a time and the use of seven non-numeric 
categories to express differences in their value (ranging from “no difference” to 
“extreme difference”). These are perceived as a convenient way to express value 
judgements by lowering cognitive load, with numerous real world applications (Bana 
e Costa & Oliveira, 2012; Bana e Costa & Vansnick, 1997).  
In the case of decision contexts requiring repeat decisions, indirect MAVT 
techniques making use of value functions are recommended in order to ensure the 
efficient and consistent scoring of alternatives as they become available for evaluation 
(Marsh et al., 2016), however indirect MAVT techniques could also benefit one-off 
decisions as they would ensure transparency between the performance of a criterion 
and the respective value preferences. 
As part of weighting, trade-offs between criteria are elicited taking the form of 
quantitative weights to convert criteria value scores into a common value scale 
(Marsh et al., 2016). Using direct rating techniques of criteria ‘importance’, as for 
example, requiring the distribution of 100 points over attributes to reflect their relative 
importance, is associated with two, potentially serious, problems: they could produce 
flatter importance weight distributions instead of ratio estimation (von Winterfeldt & 
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Edwards, 1986), which could lead to an underestimation of trade-offs between 
attributes (Peacock et al., 2007b), and might be insensitive to the attribute ranges used 
for the performance assessment (i.e. measurement scales) (Gabrielli & von 
Winterfeldt, 1978). 
 Attempting to assign ‘importance’ weights without taking into account the 
attribute ranges (i.e. measurement scales) is known to be one of the most common 
mistakes in making value trade-offs (R. Keeney, 1992; R. L. Keeney, 2002). Instead, 
the use of an indirect swing weighting technique for eliciting relative criteria weights 
is recommended as common practice through the decision analysis literature (Bana E 
Costa et al., 2012; R. Keeney & Raiffa, 1993; L. D. Phillips & Bana e Costa, 2007; 
von Winterfeldt & Edwards, 1986). This technique involves judgements of relative 
value between changes (i.e. ‘swings’) from lower performance levels to higher 
performance levels on each attribute, which is then valued between 0 and 100, the 
most valuable being anchored at 100 (von Winterfeldt & Edwards, 1986). 
Alternatively, a Discrete Choice Experiment (DCE), which is based on random utility 
theory (Amaya-Amaya et al., 2008) could be conducted to incorporate a randomness 
element on responder choices and reflect preference heterogeneity (Marsh et al., 
2016). However, the number of criteria would have to be relative small as most DCEs 
in the field of health care include up to five attributes (de Bekker-Grob et al., 2012). 
Methodological guidance on the sound design and implementation of DCEs taking the 
form of good research practice is provided elsewhere (BRIDGES ET AL 2011) 
(Johnson et al., 2013). Both of these techniques better meet the conditions needed in 
order to treat weights as scaling constants with no algebraic meaning (Marsh et al., 
2016), as in alignment with decision theory.  
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Finally, in terms of aggregating, a technique is needed for combining criteria 
scores and weights together and, more specifically, for selecting a function that allows 
the combination of the attributes in consistency with responder (e.g. stakeholders) 
preferences (Peacock et al., 2007b). The application of a simple additive (i.e. linear 
weighted average) model is the most commonly applied function in health care 
applications (Marsh et al., 2016), mainly because of its simplicity and comprehensible 
nature making it easily explained and understood by decision-makers (Belton & 
Stewart, 2002). However, its use is associated with a number of properties, the most 
restrictive of which is the existence of preference independence across criteria and 
attributes, which means that no two or more criteria, or their attributes, can 
independently have a large impact on the overall benefit of the options.  In which case 
a multiplicative or multi-linear model should be used (von Winterfeldt & Edwards, 
1986). Such models are less commonly used as they are perceived to be more 
complex to populate (R. Keeney & Raiffa, 1993); additionally, the incorrect 
aggregation of preferences through these more advanced models can result in 
considerably greater errors than additive models as evident from empirical evidence 
of simulation studies (Stewart, 1995). 
The precise choice of scoring, weighting and aggregating techniques will 
ultimately depend on a number of characteristics of the decision-making problem 
under consideration, in relation to theoretical relevance, level of precision required in 
the evaluation of the options and cognitive burden posed to stakeholders and decision-
makers (Marsh et al., 2016). Deciding on the optimal combination of modelling 
techniques represents an important topic that requires further research to better 
understand the impact of different technique combinations on the above issues and the 
results of the analysis.  
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Ultimately, results should be examined and sensitivity analysis be conducted, 
possibly in combination with robustness analysis, in order to validate the model and 
findings. Deterministic sensitivity analysis can be used to explore the impact of 
baseline weight (or scores) changes on the rankings of the options and address 
parameter uncertainty. Robustness analysis can be used as part of an n-way sensitivity 
analysis to test how simultaneous changes in the criteria scores (or weights) would 
impact the ranking of the alternative treatments. As a result, differences in viewpoints 
and any disagreements between stakeholders can be resolved, as for example by 
testing whether the ranking of the treatments might be sensitive or not to variations 
along the range of a criterion’s relative weight.   
 
5.3 Cognitive and motivational biases 
Research on behavioural decision analysis has indicated that construction of 
judgements as part of decision-making is prone to a number of biases, relating to 
faulty cognitive processes or due to motivations for preferred analysis outcomes 
(Montibeller & Winterfeldt, 2015). The presence of these biases could be present 
across the different phases of the methodological process on which the framework is 
based, and especially in the model-building, model-assessment, and model-appraisal 
phases, involving the participation of experts and decision-makers. Such biases could 
potentially reduce the quality of the model and the results of the analysis. For this 
reason, a number of de-biasing techniques should ideally be applied to overcome 
these limitations (Montibeller & Winterfeldt, 2015).  
Although the precise choice of these techniques would depend on the 
particular decision problem under consideration and the evidence available, our 
framework could support several of these. For example, in terms of cognitive biases, 
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‘equalizing bias’ relating to the allocation of similar weights to all value concerns 
could be addressed through the hierarchic elicitation of weights as part of swing 
weighting. ‘Gain-loss bias’ which occurs as alternative descriptions of a choice and its 
outcomes (which may lead to different answers) could be addressed by constructing 
value judgements in relevance to (marginal change from) a best supportive care 
option, which could be used as a reference level and act as a status quo. Myopic 
problem representation bias’ which occurs when an oversimplified problem is adopted 
and based on an incomplete mental model for the decision problem could be 
addressed by explicitly encouraging experts and decision-makers to think more about 
value concerns in the wider socioeconomic context, as through the value concerns 
captured by the Advance Value Tree. ‘Omission of important variables bias’ could be 
addressed by using group elicitation techniques so that no important variable is 
overlooked, for example by using MAVT indirect elicitation techniques as part of a 
group meeting. ‘Range insensitivity bias’ occurring when objectives are not properly 
adjusted to changes in the range of attributes could be addressed by making attribute 
ranges explicit and using a swing weighting technique. ‘Splitting bias’, which occurs 
when the structuring of the criteria affects their weights, could be addressed using 
MAVT indirect elicitation techniques instead of direct rating techniques, together 
with hierarchal estimation of relative weights such as swing weighting. 
In terms of motivational biases, a number of biases could exist because of 
peoples’ emotions, desires and motives (Montibeller & Winterfeldt, 2015): these 
include ‘affect influenced bias’ relating to the emotional predisposition for or against 
a specific outcome, ‘confirmation bias’ relating to the desire to confirm one’s belief 
leading to unconscious selectivity, ‘desirability of a positive event or consequence 
bias’ occurring when the desirability of an outcome leads to an increase in the extent 
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to which it is expected to take place (i.e. ‘wishful thinking’ or ‘optimism bias’), 
‘under-desirability of a negative event or consequence bias’ occurring when there is a 
desire to be cautious or conservative in estimates that may be related to harmful 
consequences, and ‘desirability of options or choice bias’ leading to over- or 
underestimating values or weights in a direction that favours a desired alternative. All 
of these biases could be addressed by engaging multiple experts with alternative 
points of view, collecting views from a range of different experts as stakeholders or 
decision-makers to provide different value perspectives, and using indirect MAVT 
techniques for scoring the options and weighting the criteria (Montibeller & 
Winterfeldt, 2015).  
 
5.4 Budget constraints, opportunity cost and prioritisation for resource 
allocation  
There are different perspectives on prioritisation and resource allocation most of 
which involve the ordering of alternative options as part of an appraisal or evaluation 
process, followed by choosing the best (or most attractive) combination of options 
given the available resources as part of a portfolio construction task (L. D. Phillips & 
Bana e Costa, 2007). In cost benefit analysis (CBE), which is based on the principles 
of social welfare economics, non-monetary benefits are translated into monetary 
values using willingness-to-pay, with the ratio of benefits to costs used to reflect 
value-for-money and risk often incorporated through discount rates (Great Britain, 
2003). In decision analysis (DA), decision trees are used to model the consequences 
and risks of alternative options with uncertainties about future events incorporated 
through probabilities, producing expected weighted consequences as the basis for 
ordering the options, which could be divided by their cost to give value-for-money 
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indices (Clemen, 1996). Similarly, MCDA can be used to value the consequences of 
options, where risks can be even incorporated as criteria rather than probabilities (R. 
L. Keeney & Raiffa, 1976). Although the different perspectives differ on how they 
address benefits, costs and risks, all of them agree that the best value-for-money can 
be obtained through dividing benefits by costs, essentially reflecting opportunity cost, 
which should act as the normative basis for prioritisation.  
In MCDA, value scores obtained from the model can be used to derive cost-benefit 
ratios, prioritising the most efficient options with lower cost-benefit ratios until the 
resources or any budget constraint in place are exhausted (Peacock et al., 2007a).  
More specifically, as part of health economic evaluations it is usually assumed that 
the maximum amount to be spent per unit increase in the chosen measure of outcome 
is fixed at a certain level which is referred to as the societal WTP per unit of health 
gain (Postmus et al., 2014), according to which the optimal option is derived based on 
the grounds of the highest net monetary benefit (NMB) (Karl Claxton & Posnett, 
1996). However, this maximum societal level or threshold of costs to effects ratio 
depends on the level of the available budget (Weinstein & Zeckhauser, 1973), 
therefore a decision to reimburse one intervention should in theory be followed by a 
reallocation of the remaining budget as the coverage of the intervention will influence 
the maximum ratio depending, for example, on whether it replaces a more expensive 
intervention (ratio will increase) or a less expensive intervention (ratio will decrease) 
(Postmus et al., 2014). Given that in practice the relation between the maximum cost 
per outcome ratio and available budget is often neglected and WTP thresholds are 
imposed as exogenous parameters (Al et al., 2005), it could be argued that the use of 
the NMB framework is no longer congruent with the resource allocation perspective it 
originated from (Postmus et al., 2014). In turn, it has been demonstrated that the NMB 
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framework in practice can still have a theoretical foundation when the NMB function 
is interpreted as a value function according to MAVT (Postmus et al., 2014). More 
specifically, it has been shown that the NMB framework can be seen as a special case 
of a more general stochastic MCDA approach known as stochastic multi-criteria 
acceptability analysis (SMAA), which has already been applied for the benefit-risk 
evaluation of drugs (Tervonen et al., 2011).  
 
5.5 The Advance Value Framework in Perspective 
The application of MCDA modelling techniques for the estimation of the Advance 
Value Tree through the construction of value judgements and elicitation of 
preferences based on the MAVT methodological process we have proposed (Angelis 
& Kanavos, 2016b), provides a new value framework based on MCDA principles for 
the purposes of HTA. The results of the analysis could be used to inform discussions 
and negotiations on coverage and reimbursement decisions. Overall, this value 
framework, which we call Advance Value Framework (AVF), adopts an 
encompassing societal perspective, incorporating views from the wider stakeholder 
community while assuming that the payer is the ultimate decision maker; however, 
the choice of perspective could be adapted to different circumstances and decision-
making contexts. The AVF can be used for assessing the value of new medicines 
using the comprehensive set of criteria outlined through the Advance Value Tree; in 
addition to scientific value judgments relating to therapeutic impact and safety, the 
value tree allows for the incorporation of social value judgements relating to burden 
of disease, innovation level and socioeconomic impact, all of which can be captured 
explicitly.  
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Finally, the AVF operationalises the Advance Value Tree through the implementation 
of a combination of MAVT techniques for the elicitation and aggregation of value 
preferences and can be used as a decision-making tool with the involvement of all 
stakeholders, being appropriately flexible to meet diverse requirements and readily 
adaptable across settings.  
Table 2 provides a comparative breakdown of the main features of existing value 
frameworks and the Advance Value Framework. The development of these value 
frameworks is an important step towards a more inclusive Value Based Assessment 
(VBA) process as part of decision-making contexts in health care. However an ideal 
framework should be comprehensive enough in terms of the incorporation of value 
dimensions in order to allow for an adequate capture of value, while at the same time 
giving the users flexibility for criteria selection based on their specific needs. In any 
case, individual dimensions involved should possess a number of technical 
characteristics, if they are to be combined for overall value score rankings to be 
derived (Angelis & Kanavos, 2016b; Franco & Montibeller, 2010; R. L. Keeney & 
Gregory, 2005). For example they should be operational so they can be measured and 
non-overlapping so that there is no double counting among them. Importantly, for 
some frameworks it is not clear how to operationalise performance measurement of 
the alternative options across the different value dimensions considered (so that 
options can be assessed) or how to mediate trade-offs among them, and in some cases 
such efforts seem to lack a theoretical basis, not least because they are derived in an 
arbitrary manner. Although most of the value frameworks focus mainly on the benefit 
component of the evaluation process relating to measuring the value of new 
medicines, issues relating to budget constraints or value for money considerations are 
54 
 
crucial to consider in the prioritisation of resource allocation and should be the subject 
of further research. 
 
<Table 2 about here> 
 
6. Conclusion  
By using a five-stage methodological iterative approach informed by secondary 
sources and extensive primary research and consultation, we developed a generic 
value tree (Advance Value Tree) which is embedded in decision theory. The tree 
incorporates a number of evaluation criteria that have traditionally been considered in 
the context of HTA, either explicitly in a systematic manner, or implicitly on an ad 
hoc basis. This work builds on the theoretical foundations of MAVT, based on which 
the structure of the value tree was derived, influencing the inter-relationship between 
the different criteria and the extent to which they adhere to a number of critical 
theoretical properties. We subsequently outlined the assembly of the evaluation 
criteria in the form of a generic value tree and finally we introduced a number of 
MCDA techniques for operationalising the value model into a value framework (The 
Advance Value Framework) for use by decision-makers and stakeholders. In 
undertaking the above, we focused mainly on the benefit component of the evaluation 
process relating to measuring the value of new medicines while also accounting for 
how it could be used in practice given budget constraints in order to obtain best value-
for-money. Future research could aim to test the value framework in practice, possibly 
through case studies involving specific drugs, in order to better understand potential 
advantages and limitations. 
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7. Figures and Tables 
Figure 1: Flowchart of the five-stage model building process for structuring the generic 
value tree.  
 
Validation of top-level criteria clusters and 
decomposition into lower level criteria
Lower level criteria and decomposition into 
bottom-level sub-criteria or attributes
Revision of bottom-level sub-criteria or 
attributes 
Enhanced validation of bottom-level sub-criteria 
or attributes 
Stage 1 - Systematic literature review in HTA
Stage 2 - Expert consultation
Stage 3 - Targeted examination of methodological/ grey literature
Stage 4 - Consultation with Advance-HTA partners 
Stage 5 - Wider dissemination and consultation activities 
Value dimensions considered as evaluation 
criteria in EU study countries
Top-level criteria clusters and decomposition 
into lower level criteria
Value dimensions considered as HTA criteria in 
EU study countries
Value concerns beyond current or formal HTA 
criteria 
Comprehensiveness and usefuless of the value 
tree
Comprehensiveness and usefuless of the value 
tree
  
 
Caption: Left hand side of the flow chart (blue coloured) indicates the type of evidence collected and 
tasks involved as part of each stage; right hand side of the flow chart (purple coloured) indicates the 
respective model input resulting from each stage. 
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Figure 2: Flow diagram of the systematic literature review stage. 
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Figure 3: The Advance Value Tree for new drugs evaluation. 
 
 
Caption: Hierarchical decomposition of top level criteria clusters, to middle level criteria and bottom 
level sub-criteria and attributes (from left to right), across five value domains (from top to bottom. 
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Table 1: Value dimensions considered as evaluation criteria among the study group of European countries and their intensity of use.  
France Germany Sweden England Italy Netherlands Poland Spain
Burden of disease
Severity *** ** ** ** * ** ** **
Availability *** * * *** * ** * **
Prevalence * ** * * ** ** ** **
Therapeutic
Direct endpoints *** *** *** *** *** *** *** ***
Surrogate endpoints ** ** ** ** ** ** ** **
Safety 
Adverse events *** *** *** *** *** *** *** ***
Tolerability ** ** ** ** ** ** ** **
Contra & warnings ** ** ** ** ** ** ** **
Innovation
Clinical novelty *** * * * ** ** *** **
Nature of treatment *** * * ** x * *** **
Ease of use & comfort * * ** * x * x *
Socioeconomic
Public health ** ** * ** * *** *** *
BI * *** ** *** ** ** *** **
Social productivity * ** *** ** * ** * **  
Caption: Differences in the intensity of use of the different value dimensions as evaluation criteria: Three stars (***) denote the highest intensity of use in place, i.e. 
‘mandatory/ formal/ explicit/ planned/ directly measured/ grading system available’. Two stars (**) denote a medium intensity of use in place, i.e. ‘recommended, informal/ 
implicit but planned, formal/ explicit but ad-hoc/indirectly measured’ etc. One star (*) denotes the lowest intensity of use in place, i.e. ‘optional/ informal/implicit/ad-hoc/ 
indirectly measured/ no grading system available’. No stars (x) denote that value dimension is not considered in any way as an evaluation criterion.
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Table 2: Comparison of the Advance Value Framework (AVF) with other value frameworks.  
Framework ACC/AHA ASCO 
 
ESMO 
 
ICER 
 
MSKCC 
 
NCCN 
 
MoCA AVF 
Decision 
context 
Clinical practice 
 
Shared 
decision 
making 
 
Clinical 
practice 
 
Coverage/ 
reimbursement 
 
Pricing 
 
Shared 
decision 
making 
 
Pricing and 
reimbursement 
Health 
Technology 
Assessment 
Key actor 
 
Physicians 
 
Patients - 
Physicians 
 
Physicians 
 
Payer 
 
Payer-Provider 
 
Patients - 
Physicians 
 
Payers - 
Manufacturers 
All 
stakeholders 
Value 
parameters 
-Clinical benefit 
vs. risks 
-"Value" (cost-
effectiveness) 
-Clinical 
benefit 
(efficacy) 
-Toxicity 
(safety) 
-Cost 
(efficiency) 
-Variability of 
estimated 
Hazard Ratio 
-Observed 
absolute 
difference in 
treatment 
outcomes: 
 
-Clinical care 
value 
-Health system 
value 
-Dollars per 
life year 
-Toxicity  
-Novelty 
-Cost of 
development 
-Rarity 
-Population 
burden of 
disease 
 
-Efficacy of 
regimen 
-Safety of 
regimen  
-Quality of 
evidence 
-Consistency 
of evidence 
-Affordability 
of regimen  
-Alternatives 
available/ 
unmet need 
-Relative 
effectiveness 
-Response rate 
-Degree of 
certainty 
-Burden of 
disease 
-Therapeutic 
impact 
-Safety profile 
-Innovation 
level 
-Socio-
economic 
impact 
Conceptual 
basis 
Stakeholder 
consultation 
(writing 
committee) 
Stakeholder 
consultation 
(ASCO Value 
in Cancer 
Care Task 
Force) 
Stakeholder 
consultation 
(ESMO Task 
Force with 
input from the 
ESMO faculty 
and a team of 
biostatisticians, 
Stakeholder 
consultation 
(Input from the 
ICER Policy 
Development 
Group, 
involving 
representatives 
Developed by  
single 
clinician/ 
epidemiologist 
Stakeholder 
consultation 
(NCCN panel 
members) 
 
Stakeholder 
consultation 
(the MoCA 
working group 
that was 
formed by 
volunteers 
from a number 
Literature 
review; 
Stakeholder 
consultation 
(Advance-HTA 
partners and 
workshop 
participants, 
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followed by 
the ESMO-
MCBS Task 
Force, the 
ESMO 
Guidelines 
Committee and 
a range of 
invited 
experts)  
 
from all major 
stakeholder 
groups) 
of EU 
countries) 
national 
experts); 
Decision 
theory 
 
Strengths  Quality of 
evidence (LOE) 
explicitly ranked; 
class of 
recommendation 
given separately 
and not 
averaged 
together with 
the level/quality 
of evidence as a 
single metric 
Net Health 
Benefit score 
and costs 
illustrated 
side by side to 
facilitate the 
decision 
making 
process of 
patients by 
making full 
informed 
decisions  
 
Both the 
variability of 
the estimated 
HR and the 
observed 
absolute 
difference in 
treatment 
outcomes are 
explicitly 
addressed 
 
Integration of a 
technology's 
value-for-
money with its' 
budget impact 
 
A range of 
domains 
incorporated, 
both relating 
to the drug 
and the 
disease 
Easy and 
simple to 
comprehend 
visual output 
 
Easy to 
comprehend 
and practical to 
use because of 
its simplicity 
 
 
Multiplicity of 
explicit value 
domains; 
Assignment of 
quantitative 
relative 
weights; 
Transparent; 
Engagement 
of all 
stakeholders; 
Grounds on 
decision 
theory 
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8. Appendices  
1. The academic and research institutions of the Advance-HTA consortium 
included, the following academic-research institutions with health economics 
and/or HTA centers: London School of Economics and Political Science 
(LSE), London School of Hygiene and Tropical Medicine (LSHTM), Instituto 
Superiore di Sanita (ISS), Universidad de Castilla – La Mancha (UCLM), 
Institute za Ekonomska Raziskovanja (IER), Technische Universitaet Berlin 
(TUB), Escuela Andaluza de Salud Publica (EASP), Universite Paris XII - Val 
de Marne (UPEC), and University College London (UCL); the following four 
HTA bodies: NICE International, Agencja Oceny Technologii Medycznych 
(AOTM), Tandvårds- och läkemedelsförmånsverket (TLV), and Haute 
Autorité de Santé (HAS); the following HTA research network: European 
Network for Health Technology Assessment (EUnetHTA); the following 
coordinating patient and health care professional organisation: European Brain 
Council (EBC); the following international public health organisation: Pan 
American Health Organisation (PAHO).  
2. The available clinical evidence used for the assessment of therapeutic benefit 
will in most cases be sourced from explanatory trials that reflect ideal 
conditions, conducted on a highly selected group of patients and under strictly 
controlled environments while ensuring regimen compliance. In contrast, 
pragmatic trials are conducted under real world settings and on patients 
representing the full population spectrum that may show varying compliance 
(Godwin et al., 2003). Indeed, evidence from electronic monitoring for a range 
of diseases including hypertension, glaucoma, seizure disorders and others, 
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indicate that good adherence to prescribed regimens is only observed in 
between 50% and 60% of patients, with 5% to 10% adhering poorly and 30% 
to 45% adhering to an intermediate but widely variable degree (Cramer & 
Mattson, 1991; Gordon & Kass, 1991; Kass et al., 1986; Kruse & Weber, 
1990; Rudd, 1995). Ergo, and unless the clinical evidence are coming from 
pragmatic trials resembling real world conditions, acknowledging that there is 
an impact on health outcomes from (un)ease and/or (un)convenient regimens 
could act as an adjustment or “fixture” towards the reflection of a more 
realistic clinical picture.  
 
